GYREGYRE THERAPEUTICS, INC.
- GlobeNewswire
Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update
Q2 2026 revenue of $29.1 million; GAAP basic EPS: $(0.12) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F351 (hydronidone) for CHB-induced liver fibrosis accepted by China’s CDE in May ...
- GlobeNewswire
Gyre Therapeutics Appoints Three New Members to its Board of Directors
SAN DIEGO, July 16, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. ("Gyre", "Gyre Therapeutics" or the "Company") (NASDAQ:GYRE), an innovative, commercial-stage biopharmaceutical company with ...
- GlobeNewswire
Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. ("Gyre", "Gyre Therapeutics" or the "Company") (NASDAQ:GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United ...
- GlobeNewswire
Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update
Q1 2026 revenue of $22.5 million; GAAP basic EPS: $(0.10) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F351 (hydronidone) for CHB-associated liver fibrosis submitted to China's CDE in ...
- GlobeNewswire
Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company
Post-closing combined company has revenue-producing commercial asset and a robust pipeline of products and product candidates to address multiple therapeutic areas with a focus on fibrosis and inflammatory diseases.China ...
- GlobeNewswire
Gyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and Pipeline
Acquisition will create a U.S.- and China-based fully integrated biopharmaceutical company with revenue-producing commercial assets and a robust pipeline of degraders, targeting inflammatory diseases and cancers.Access ...
- GlobeNewswire
Gyre Therapeutics Announces Alignment with China's CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting
Gyre Pharmaceuticals completed a Pre-NDA meeting with China's CDE, which agreed that the existing Phase 3 clinical data support a conditional approval filing for Hydronidone and priority review eligibility, subject to ...
- GlobeNewswire
Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update
Net income of $5.9 million and $11.2 million for the three and nine months ended September 30, 2025, respectively Full-year revenue guidance revised to $115-118 million (from $118 - $128 million previously) due to ...
- GlobeNewswire
Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis
SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (NASDAQ:GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by ...
- GlobeNewswire
Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025
SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems ...
- Analyst Upgrades
Jefferies Initiates Coverage On Gyre Therapeutics with Buy Rating, Announces Price Target of $16
Jefferies analyst Roger Song initiates coverage on Gyre Therapeutics with a Buy rating and announces Price Target of $16. ...
- SEC
8-K Form - Current report, items 8.01 and 9.01 - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
Current report, items 8.01 and 9.01 ...
- GlobeNewswire
Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems ...
- SEC
4 Form - Statement of changes in beneficial ownership of securities - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
Statement of changes in beneficial ownership of securities ...
- SEC
3 Form - Initial statement of beneficial ownership of securities - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
Initial statement of beneficial ownership of securities ...
- Analyst Upgrades
Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker
HC Wainwright starts Gyre Therapeutics coverage with a Buy rating, citing hydronidone's $6 billion potential and strong fibrosis treatment pipeline. ...
- Analyst Upgrades
HC Wainwright & Co. Initiates Coverage On Gyre Therapeutics with Buy Rating, Announces Price Target of $18
HC Wainwright & Co. analyst Matthew Keller initiates coverage on Gyre Therapeutics with a Buy rating and announces Price Target of $18. ...
- GlobeNewswire
Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors
SAN DIEGO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems ...
- GlobeNewswire
Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update
Net income of $1.6 million and $5.3 million for the three and six months ended June 30, 2025, respectively; reaffirms full-year revenue guidance of $118-128 million Ping Zhang, Executive Chairman, ...
- SEC
4 Form - Statement of changes in beneficial ownership of securities - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
Statement of changes in beneficial ownership of securities ...
- GlobeNewswire
Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
SAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems ...
- SEC
4 Form - Statement of changes in beneficial ownership of securities - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
Statement of changes in beneficial ownership of securities ...
- SEC
4 Form - Statement of changes in beneficial ownership of securities - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
Statement of changes in beneficial ownership of securities ...
- SEC
4 Form - Statement of changes in beneficial ownership of securities - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
Statement of changes in beneficial ownership of securities ...
- SEC
4 Form - Statement of changes in beneficial ownership of securities - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
Statement of changes in beneficial ownership of securities ...